Capital and Industry Gather to Explore the Path of Cell Therapy Development

Project Pitch 1:

Translation of Innovative Drugs for Gene and Cell Therapy

This project is one of the few CGT enterprises in China to have established a product matrix integrating oncolytic virus gene therapy, immune cell therapy, and stem cell therapy. It has built a scalable GMP-grade manufacturing and quality control system, and constructed a sustainable pipeline portfolio focused on oncology and regenerative medicine.This financing round primarily focuses on advancing the clinical development of innovative pipeline assets, with core assets including:

(1) E10B (Recombinant Human Interferon-gamma Adenovirus Injection): An adenovirus vector-based immunomodulatory agent that has completed Phase Ia clinical studies in advanced castration-resistant prostate cancer and is currently undergoing Phase Ib/II clinical studies.

(2) E10H (Autologous NK Cell Injection): The first non-genetically modified NK cell therapy in China, currently in Phase II clinical trials for gastrointestinal tumors, and has already been approved for clinical application in Beidaihe. Clinical filings under Order No. 818 are simultaneously being processed at multiple hospitals.

(3) E10I (Umbilical Cord Mesenchymal Stem Cell Injection): Currently conducting a double-blind Phase I/IIa clinical trial for the indication of Type 2 Diabetes. The single-dose administration for the first dose cohort has been completed, and preliminary efficacy has been observed;

(4) The multi-target oncolytic adenovirus (E10K series) has obtained approval for Phase I clinical trials.

Furthermore, the company has CAR-NK therapies and chip-validated personalized cancer vaccines nearing clinical trials, serving as platform extensions to enhance long-term value.

Project Pitch 2:

In Vivo mRNA-Encoded TCR-T Therapy for the Treatment of Tumors and Infectious Diseases

This project is a clinical-stage biotechnology company incubated by the Agency for Science, Technology and Research (A*STAR) in Singapore, focusing on and leading the global development of mRNA-encoded TCR-T cell therapies for the treatment of solid tumors and infectious diseases.

Project Highlights:

1. The core product is an mRNA-encoded TCR-T cell therapy targeting the hepatitis B virus (HBV) for the treatment of HBV-related diseases. It is the first cell therapy globally to receive FDA approval for conducting international multicenter Phase II clinical trials in liver cancer, and has been granted FDA Fast Track designation and Orphan Drug status.

2. In September 2025, the FDA approved the expansion of the Phase 1b/2 IND clinical trial for the treatment of chronic hepatitis B; implicit approval for the Phase 1/2 IND clinical trial has also been obtained from China’s NMPA.

Project Pitch 3:

LANEX-DC® Therapeutic Cancer Vaccine

This ProjectIt is an advanced cell therapy manufacturing enterprise dedicated to the treatment of malignant solid tumors, one of the few industry leaders in China that has achieved commercial availability of its products in medical institutions, and is recognized as a National High-Tech Enterprise and a Guangdong Province Specialized, Refined, Differential, and Innovative Enterprise.

Project Highlights:

1. In 2018, the Company introduced LANEX-DC®, an autologous dendritic cell injection from Germany, to Macau and Guangzhou in the Greater Bay Area; the product was approved for marketing in Germany and the European Union in 2021 as an Advanced Therapy Medicinal Product (ATMP); it received clinical trial approval from the National Medical Products Administration (NMPA) in 2023 under Category 3.2 for innovative drugs; in 2025, leveraging the national “first-to-try, first-to-implement” policy in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, it achieved market launch and clinical application; in April 2026, it was ranked first among the inaugural batch of key incubation projects for clinical research on new biomedical technologies in the Guangzhou Development District.

2、The company has established five GMP-compliant production workshops in Huangpu District, Guangzhou. Its primary product is an autologous dendritic cell therapeutic injection for immune-related solid tumors. It has been approved for fee-based use at Hainan Boao Super Hospital for the indications of pancreatic cancer and colorectal cancer, making it one of only over twenty cell therapy products nationwide approved for compliant, fee-based clinical use. The company implements a “factory production–hospital fee-based treatment” dual-point sales model through head-to-head multidisciplinary team (MDT) consultations with hospitals.

Project Pitch 4:

Cell-Vaccine Therapeutics for the Functional Cure of HIV

Established in 2017 by high-level talents introduced by the Organization Department of the CPC Central Committee, this project is based in Science City, Huangpu District, Guangzhou. Its core team comprises senior immunologists and virologists, specializing in the research and development of CAR-T immune cell therapy technologies for antiviral and antitumor applications.

Project Highlights:

1. The company is the first globally to employ CAR-T cell therapy for clearing the HIV-1 viral reservoir in patients, while simultaneously developing a broad-spectrum therapeutic vaccine for AIDS.

2. The company holds multiple invention patents and possesses sustained new drug development capabilities; it was recognized as a National High-Tech Enterprise in 2022. In 2025, this project received support as a “Disruptive Technology Innovation Project” from the Beijing-Tianjin-Hebei National Technology Innovation Center.

Project Pitch 5:

Directionally Inducible Universal hiPSCsResearch on the Treatment of Neurodegenerative Diseases

This project is a cell therapy company centered on human induced pluripotent stem cell (hiPSC) technology, focusing on the development of druggable hiPSC-derived cell therapy products. The company’s core technology revolves around “directionally inducible universal hiPSCs,” leveraging multiple technological innovations to overcome the bottlenecks of traditional stem cell therapies and providing a novel solution for the treatment of neurodegenerative diseases.

Project Highlights:

1. Low immunogenicity: Allogeneic transplantation can be achieved without immunosuppressants, reducing treatment risks and costs;

2. Efficient Differentiation: Achieves directed differentiation into various neuronal types via the Tet-on system, enhancing therapeutic precision and efficacy;

3. Long-term Survival and Integration: Stem cells can survive for extended periods in vivo and effectively integrate into the host neural network, significantly improving patients' neurological function.

❖ Project Submission Email：BP@gdmv.cn

❖ Email Subject:[Roadshow + Person in Charge Name + Project Name]